$680 Million is the total value of Broadfin Capital, LLC's 50 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 114.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IWM | New | ISHARES TRput | $67,420,000 | – | 400,000 | +100.0% | 9.92% | – |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $55,062,000 | +3.7% | 4,894,361 | +18.0% | 8.10% | -3.0% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $41,347,000 | -5.2% | 2,053,991 | +37.4% | 6.08% | -11.3% |
| ZGNX | Buy | ZOGENIX INC | $32,632,000 | +18.6% | 657,898 | +5.7% | 4.80% | +10.9% |
| ADMA | Buy | ADMA BIOLOGICS INC | $27,720,000 | +89.1% | 4,463,829 | +37.4% | 4.08% | +76.8% |
| TNDM | Buy | TANDEM DIABETES CARE INC | $24,551,000 | +95.4% | 573,079 | +0.4% | 3.61% | +82.7% |
| XBI | New | SPDR SERIES TRUSTput | $15,339,000 | – | 160,000 | +100.0% | 2.26% | – |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $15,156,000 | – | 850,000 | +100.0% | 2.23% | – |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $13,487,000 | +260.4% | 2,493,021 | +136.5% | 1.98% | +237.0% |
| IART | Buy | INTEGRA LIFESCIENCES HLDGS C | $12,948,000 | +23.0% | 196,572 | +20.3% | 1.90% | +15.0% |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $12,431,000 | -11.5% | 2,563,096 | +9.5% | 1.83% | -17.3% |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $12,260,000 | -26.6% | 2,792,773 | +2.5% | 1.80% | -31.4% |
| BDSI | Buy | BIODELIVERY SCIENCES INTL IN | $12,250,000 | -3.0% | 4,375,066 | +2.2% | 1.80% | -9.3% |
| TLGT | Buy | TELIGENT INC NEW | $12,059,000 | +16.2% | 3,052,852 | +1.8% | 1.78% | +8.6% |
| XENE | New | XENON PHARMACEUTICALS INC | $11,821,000 | – | 895,553 | +100.0% | 1.74% | – |
| SRRA | Buy | SIERRA ONCOLOGY INC | $6,954,000 | +11.5% | 4,090,344 | +94.2% | 1.02% | +4.2% |
| XENT | New | INTERSECT ENT INC | $6,733,000 | – | 234,200 | +100.0% | 0.99% | – |
| SLGL | Buy | SOL GEL TECHNOLOGIES | $6,358,000 | +27.2% | 847,700 | +30.9% | 0.94% | +18.9% |
| ANGO | New | ANGIODYNAMICS INC | $6,284,000 | – | 289,035 | +100.0% | 0.92% | – |
| QTNT | Buy | QUOTIENT LTD | $6,075,000 | +72.0% | 804,700 | +83.0% | 0.89% | +60.8% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $5,700,000 | – | 150,000 | +100.0% | 0.84% | – |
| IDRA | New | IDERA PHARMACEUTICALS INC | $5,607,000 | – | 629,340 | +100.0% | 0.82% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $5,444,000 | – | 62,200 | +100.0% | 0.80% | – |
| TSRO | New | TESARO INC | $4,084,000 | – | 104,700 | +100.0% | 0.60% | – |
| DXCM | New | DEXCOM INC | $3,462,000 | – | 24,200 | +100.0% | 0.51% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $3,317,000 | – | 150,000 | +100.0% | 0.49% | – |
| VRAY | New | VIEWRAY INC | $2,340,000 | – | 250,000 | +100.0% | 0.34% | – |
| LJPC | New | LA JOLLA PHARMACEUTICAL COcall | $2,013,000 | – | 100,000 | +100.0% | 0.30% | – |
| VCEL | New | VERICEL CORP | $1,876,000 | – | 132,600 | +100.0% | 0.28% | – |
| OMED | New | ONCOMED PHARMACEUTICALS INC | $424,000 | – | 200,000 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
| HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
| LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
| RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
| ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
| RETROPHIN INC | 23 | Q3 2019 | 7.0% |
| ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
| MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
| CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
| ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
| LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
| STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
| Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
| Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
| Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
| Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
| ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
| AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-03-22 |
| 4 | 2022-02-15 |
| 4 | 2022-01-31 |
| 4 | 2021-11-22 |
| 4 | 2021-11-15 |
| 4 | 2021-11-09 |
| 4 | 2021-08-10 |
| 4 | 2021-05-13 |
| SC 13G/A | 2021-01-04 |
| SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.